Last reviewed · How we verify
CS0159
At a glance
| Generic name | CS0159 |
|---|---|
| Also known as | Investigational drug (FXR agonist), Pleacbo, Placebo |
| Sponsor | Cascade Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) (PHASE2)
- CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) (PHASE2)
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA (PHASE3)
- A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury (PHASE1)
- Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM (NA)
- Study of [14C]CS0159 in China Healthy Subjects (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CS0159 CI brief — competitive landscape report
- CS0159 updates RSS · CI watch RSS
- Cascade Pharmaceuticals, Inc portfolio CI